Name: TG Therapeutics, Inc. (TGTX) Financial Statements
Creator: FinSpry

TG Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

TG Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018
Revenue & Gross Profit
Revenue	329.00	233.66	2.79	6.69	0.15	0.15	0.15
Cost of Revenue	38.49	14.13	0.27	0.79	0.00	0.00	0.00
Gross Profit	290.52	219.53	2.52	5.90	0.15	0.15	0.00
Operating Expenses
Research & Development	94.29	76.19	125.35	198.53	165.90	142.36	153.79
Selling, General & Administrative	154.30	122.71	95.48	90.86	107.85	3.98	20.76
Operating Expenses	248.59	198.90	220.84	351.46	273.75	169.21	174.55
Operating Income	41.93	20.63	-218.32	-344.77	-273.59	-169.06	-174.40
Other Income/Expense
Interest Income	0.00	0.00	0.00	0.00	0.00	0.00	0.86
Interest Expense	24.03	12.62	-10.19	5.64	-6.33	0.00	0.88
Other Income/Expense	7.69	5.04	4.70	-2.31	0.54	-1.47	1.80
Income
Income Before Tax	25.59	13.06	-223.81	-286.04	-279.38	-150.00	-173.48
Income Tax Expense	2.21	0.39	-7.24	-73.10	-58.67	-36.30	0.00
Net Income	23.38	12.67	-223.81	-348.10	-279.38	-172.87	-173.48
Net Income - Continuous Operations	23.38	12.67	-223.81	-348.10	0.00	0.00	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	49.90	26.10	-218.01	-341.97	-273.44	-146.54	-172.38
EBIT	49.62	25.68	-218.32	-342.46	-273.59	-147.34	-172.61
Depreciation & Amortization	0.28	0.42	0.30	0.49	0.16	0.00	0.00
Earnings Per Share
Basic EPS	-	-	-2.00	-3.00	-2.00	-2.00	-2.00
Diluted EPS	-	-	-2.00	-3.00	-2.00	-2.00	-2.00
Basic Shares Outstanding	145.32	141.96	135.41	132.22	115.33	88.37	75.47
Diluted Shares Outstanding	160.34	148.51	135.41	132.22	115.33	88.37	75.47